SciClone Pharmaceuticals
SciClone profit up 4.3% to RMB622.7m in H1 2021
SciClone profit up 4.3% to RMB622.7m in H1 2021
Its revenue rose 14.7% to RMB1.3b in the same period.
Most Read
1. Agentic AI cuts drug development timelines: report 2. Biopharma firms face $275b patent cliff as returns stall 3. iX Biopharma secures $52.8m US contract for pain reliever trials 4. DBS’ $72m loan to PLife REIT to finance elder care in Japan 5. Aging population drives demand for durable medical equipment marketResource Center
Read Here
Advertise
Sign Up
Events
Event News
He discusses how healthcare systems in Asia Pacific need to evolve beyond simply expanding coverage and towards delivering equitable, sustainable, and high-impact care.
